Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Published in: Health & Medicine
  • hi tulsi.
    nice to see your presentation in slideshare.Your presentation is lucid and very informative..Well done!!!!! splendid job.
    Are you sure you want to  Yes  No
    Your message goes here


  1. 1. SERM & SERD Tulasi Raman P
  2. 2. ESTROGEN – PHYSIOLOGICAL EFFECTS On blood: Decreased antithrombin III Increased Factor II, VII, IX, X Thrombolic predisposition Lipid profile: Increase in HDL Decrease in LDL Increase in triglycerides
  3. 3. Uterine endometrium Induction of secretory phase Mammary glands Development of alveo-lobular system Cervix Viscous, scanty mucus secretion Bones: Maintains bone mass Decrease in bone resorption
  4. 4. FSH / LH secretion Feedback control Carbohydrate metabolism Increases basal insulin levels Insulin response to glucose Fat deposition Increased Increased appetite
  5. 5. WHAT IS SERM ?  Selective Estrogen Receptor Modulator (SERM) are non steroidal synthetic agents whose agonist or antagonist activities on estrogen receptor (ER) are tissue selective.
  6. 6. SERM - DRUGS  Prototype : Tamoxifen  Tamoxifen analogs : Toremifine, Droloxifene, Idoxifene  Fixed ring compounds : Raloxifene, Lasofoxifene, Arzoxifene, Miproxifene, Levormeloxifene, EM652
  7. 7. CLOMIPHENE Orally active SERM Acts as competitive antagonist of ER in hypothalamus Inhibits negative feedback effects on the release of GnRH Increases the pulse frequency of GnRH
  8. 8. CLOMIPHENE - USES  Infertility due to anovulation  Male infertility due to oligozoospermia  In vitro fertilization
  9. 9. CLOMIPHENE – ADVERSE EFFECTS  Twins / Multiple pregnancy  Ovarian enlargement  Polycystic ovaries (can rupture leading to internal hemorrhage)  Hot flushes  Weight gain  Reversible alopecia  Vertigo
  10. 10. TAMOXIFEN  Potent ER antagonist at: Breast Blood vessel Peripheral sites  ER agonist at: Uterus Bone Liver Pitutary
  11. 11. TAMOXIFEN - MOA Competitive inhibitor of estradiol binding to the ER Binding of estradiol & SERM to the estrogen binding sites of the ER’s initiate a change in conformation of the ER, dissociates the ER form heat-shock proteins and inhibition of ER dimerisation
  12. 12. TAMOXIFEN - MOA Up regulates Transforming Growth Factor β (TGF- β) Decreases total serum cholesterol Decreases LDL cholesterol Increases apolipoprotein A1
  13. 13. TAMOXIFEN - PHARMACOKINETICS Readily absorbed on oral administration Peak concentration – 3-7 hours Steady state – 4-6 weeks Oral dose 20mg/day At high doses 200mg/day can cause retinal degeneration
  14. 14. TAMOXIFEN - PHARMACOKINETICS Metabolites CYP3A4/5  N desmethyl tamoxifen CYP2D6  4 hydroxytamoxifen 4 hydroxy N desmethyltamoxifen (Retains affinity) T ½ Parent drug – 7days Metabolites – 14 days Enterohepatic circulation Excreted in stool
  15. 15. TAMOXIFEN – USES Breast Carcinoma – Pre & Postmenopausal Prevents post-menopausal osteoporosis Improves bone density Decreases incidences of Coronary Artery Disease (CAD) Improves lipid profile
  16. 16. TAMOXIFEN – ADVERSE EFFECTS Hot flushes Menstrual irregularities Nausea Vomiting Anorexia Hair loss Vaginal bleeding and discharge Pruritis vulvae and dermatitis Atrophy of lining of vagina
  17. 17. TAMOXIFEN RESISTANCE Polymorphism of CYP2D6 Cross talk between ER & HER2/neu pathway Interaction between PAX2 and the ER coactivator AIB-1 / SRC-3 determine tamoxifen response in breast cancer cells
  18. 18. TOREMFINE Triphenylethylene derivative of Tamoxifen Similar pharmacological profile Used to treat Brest cancer with ER+ or unknown receptor states Not hepatocarcinogenic in experimental animals
  19. 19. WHAT IS SERD ? Selective Estrogen Receptor Down regulator (SERD) are pure anti- estrogens. Paradoxically SERM down-regulates ER’s and also promotes degradation of ER’s by proteosomal enzymes
  20. 20. SERD - DRUGS Fulvestrant – Prototype SR16234 ZK191703 RU58668 ZK191703
  21. 21. FULVESTRANT Steroidal anti-estrogen that binds to the ER with an affinity >100 times that of tamoxifen Pure anti-estrogen
  22. 22. FULVESTRANT - MOA  Inhibits binding of estrogen  Alters the receptor structure such that the receptor is targeted for proteosomal degradation  Inhibits receptor dimerisation  Decreases number of ER molecules in cells  ER downregulation  abolishes ER mediated transcription of estrogen dependant genes
  23. 23. FULVESTRANT - PHARMACOKINETICS Given i.m. Max plasma concentration: 7 days t ½: 40 days Steady state 3-6 months Dosing Loading dose 500mg on day 0 250 mg on 14th & 28th day 250 mg every month
  24. 24. FULVESTRANT - PHARMACOKINETICS Extensive, rapid distribution & extensive protein binding CYP3A4  metabolites <1% of drug is excreted intact in urine
  25. 25. FULVESTRANT - USES Tamoxifen resistant Breast Cancer
  26. 26. FULVESTRANT – ADVERSE EFFECTS Nausea Asthma Pain Vasodilation Headache
  27. 27. RALOXIFENE Antiestrogen effect at: Breast Endometrial tissue Estrogenic effect at: Bone Lipid metabolism Blood coagulation
  28. 28. RALOXIFENE Dose dependant increase in osteoblast activity and decreased osteoclast action Increases Bone density Maintains favorable lipid profile Does not stimulate endometrial carcinoma No risk of endometrial cancer
  29. 29. RALOXIFENE - PHARMACOKINETICS Orally absorbed Poor bioavailability Extensive first pass metabolism in liver Large aVd & longer t ½ Hence once a day administration 60mg/day
  30. 30. RALOXIFENE - USES Prevention of osteoporosis in post- menopausal women Decrease risk of Breast cancer (ER positive) Decreases risk of vertebral compression fracture Alternative for Hormone Replacement Therapy
  31. 31. RALOXIFENE – ADVERSE EFFECTS Hot flushes Leg cramps Increased risk of Deep Vein Thrombosis Pulmonary embolism Estrogenic effect on blood coagulation
  32. 32. ORMELOXIFENE Estrogen antagonist at breast and uterus Has anti-estrogen activity as well as anti-progestogenic action
  33. 33. ORMELOXIFENE - USES Dysfunctional Uterine Bleeding (DUB) Non-hormonal oral contraceptive Investigated for Osteoporosis Breast cancer Endometrial cancer
  34. 34. ORMELOXIFENE - USES Nausea Headache Fluid retention Weight gain
  36. 36. LASOFOXIFENE Investigated for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy in postmenopausal women. Increased endometrial thickness. Lasofoxifene was not approved by the US FDA for the treatment of vaginal atrophy.
  37. 37. OSPEMIFENE Similar effect on most markers of bone resorption and bone formation compared with raloxifene Does not induce vasomotor symptoms in postmenopausal women Increased endometrial thickness and uterine volume
  38. 38. ARZOXIFENE  Treatment and prevention of breast cancer  Reduction in vertebral fractures and breast cancer in postmenopausal women  Failed to meet secondary endpoints of reduction in non-vertebral fractures and cardiovascular events and improvements in cognitive function  The drug company announced they are discontinuing further development of the drug and would not seek regulatory approval
  39. 39. BAZEDOXIFENE Prevention and treatment of postmenopausal osteoporosis Favorable effects on lipid parameters total cholesterol low-density lipoprotein cholesterol high-density lipoprotein cholesterol
  40. 40. THANK YOU !